Author: admin

“Bronchiolitis Obliterans Syndrome market growth”

The Bronchiolitis Obliterans Syndrome market report also offers comprehensive insights into the Bronchiolitis Obliterans Syndrome market size, share, Bronchiolitis Obliterans Syndrome epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Bronchiolitis Obliterans Syndrome market size growth forward.

Some of the key highlights from the Bronchiolitis Obliterans Syndrome Market Insights Report:

• In 2022, the Bronchiolitis Obliterans Syndrome market size across the 7MM was around USD 58 million and is projected to grow throughout the study period (2019–2032).

• Several pharmaceutical companies, including Zambon Pharma, Incyte Corporation, Genentech, GlaxoSmithKline, and Altavant Sciences, are actively involved in developing treatments for Bronchiolitis Obliterans Syndrome.

Strategise your business goals by understanding market dynamics @ Bronchiolitis Obliterans Syndrome Market Landscape

Bronchiolitis Obliterans Syndrome Overview

DelveInsight’s report on the Bronchiolitis Obliterans Syndrome (BOS) treatment market provides a comprehensive overview of the condition, which is an inflammatory disease affecting the smallest airways of the lungs. BOS leads to scarring and airway obstruction due to damage and inflammation caused by various factors, including exposure to chemicals (such as nitrogen oxides, ammonia, welding fumes, and food flavoring fumes), respiratory infections, rheumatoid arthritis, or graft-versus-host disease after lung or hematopoietic cell transplantation.

Symptoms of BOS vary, with some individuals remaining asymptomatic. Common signs include shortness of breath, dry cough, wheezing, and fatigue, which typically develop over weeks or months and may worsen with physical exertion. In some cases, additional symptoms like skin rashes may appear due to chemical exposure.

The condition is linked to lung damage caused by inhaling irritants such as chlorine, sulfur dioxide, and diacetyl, as well as infections from respiratory syncytial virus, adenovirus, or Mycoplasma pneumonia. As BOS progresses, symptoms intensify, highlighting the need for early detection and effective treatment strategies.

Do you know the treatment paradigms for different countries? Download our Bronchiolitis Obliterans Syndrome Market Sample Report

Bronchiolitis Obliterans Syndrome Epidemiology Insights

• In 2022, the estimated number of diagnosed prevalent cases of Bronchiolitis Obliterans Syndrome in the 7MM was around 32,600. This number is anticipated to increase throughout the study period from 2019 to 2032.

Bronchiolitis Obliterans Syndrome Epidemiology Segmentation

DelveInsight’s Bronchiolitis Obliterans Syndrome market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Bronchiolitis Obliterans Syndrome historical patient pools and forecasted Bronchiolitis Obliterans Syndrome patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Bronchiolitis Obliterans Syndrome Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

• Bronchiolitis Obliterans Syndrome Prevalence

• Age-Specific Bronchiolitis Obliterans Syndrome Prevalence

• Gender-Specific Bronchiolitis Obliterans Syndrome Prevalence

• Diagnosed and Treatable Cases of Bronchiolitis Obliterans Syndrome

Visit for more @ Bronchiolitis Obliterans Syndrome Epidemiological Insights

Bronchiolitis Obliterans Syndrome Market Outlook

Treatment for Bronchiolitis Obliterans Syndrome (BOS) following lung transplantation or allo-HSCT primarily involves enhancing immunosuppression, as it is considered a form of chronic rejection. This includes increasing or adding immunosuppressive agents such as tacrolimus, cyclosporine, mycophenolate mofetil, and prednisone. Azithromycin has been shown to improve lung function and reduce the incidence of BOS. Additionally, a combination of inhaled fluticasone, oral montelukast, and Zithromax can help slow lung function decline in BOS post-HSCT.

Managing gastroesophageal reflux is also recommended to mitigate BOS progression. In cases where the condition becomes severe and progressive, lung retransplantation may be necessary. Extracorporeal photopheresis has been successfully used to slow lung function decline. Some clinics have recently explored the off-label use of nintedanib and pirfenidone, demonstrating potential clinical efficacy and safety, though further research is needed to establish these drugs as viable therapeutic options for BOS.

Bronchiolitis Obliterans Syndrome Emerging Drugs

• Liposomal Cyclosporine A: Zambon Pharma

• MPH966 (alvelestat): Mereo Biopharma

Bronchiolitis Obliterans Syndrome Key Companies

• Zambon Pharma

• GlaxoSmithKline

• Incyte Corporation

• Mereo Biopharma

• Genentech, and others

For more information, visit Bronchiolitis Obliterans Syndrome Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Bronchiolitis Obliterans Syndrome Market Report:

• 11 Years Forecast

• 7MM Coverage

• Descriptive overview of Bronchiolitis Obliterans Syndrome, causes, signs and symptoms, diagnosis, treatment

• Comprehensive insight into Bronchiolitis Obliterans Syndrome epidemiology in the 7MM

• Bronchiolitis Obliterans Syndrome marketed and emerging therapies

• Bronchiolitis Obliterans Syndrome companies

• Bronchiolitis Obliterans Syndrome market drivers and barriers

Table of Contents:

1 Bronchiolitis Obliterans Syndrome Market Key Comprehensive Insights

2 Bronchiolitis Obliterans Syndrome Market Report Introduction

3 Competitive Intelligence Analysis for Bronchiolitis Obliterans Syndrome

4 Bronchiolitis Obliterans Syndrome Market Analysis Overview at a Glance

5 Executive Summary of Bronchiolitis Obliterans Syndrome

6 Bronchiolitis Obliterans Syndrome Epidemiology and Market Methodology

7 Bronchiolitis Obliterans Syndrome Epidemiology and Patient Population

8 Bronchiolitis Obliterans Syndrome Patient Journey

9 Bronchiolitis Obliterans Syndrome Treatment Algorithm, Bronchiolitis Obliterans Syndrome Current Treatment, and Medical Practices

10 Key Endpoints in Bronchiolitis Obliterans Syndrome Clinical Trials

11 Bronchiolitis Obliterans Syndrome Marketed Therapies

12 Bronchiolitis Obliterans Syndrome Emerging Therapies

13 Bronchiolitis Obliterans Syndrome: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Bronchiolitis Obliterans Syndrome

16 Bronchiolitis Obliterans Syndrome Market Key Opinion Leaders Reviews

18 Bronchiolitis Obliterans Syndrome Market Drivers

19 Bronchiolitis Obliterans Syndrome Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Bronchiolitis Obliterans Syndrome Epidemiology 2032

DelveInsight’s “Bronchiolitis Obliterans Syndrome – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Bronchiolitis Obliterans Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Bronchiolitis Obliterans Syndrome Pipeline 2024

“Bronchiolitis Obliterans Syndrome Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Bronchiolitis Obliterans Syndrome market. A detailed picture of the Bronchiolitis Obliterans Syndrome pipeline landscape is provided, which includes the disease overview and Bronchiolitis Obliterans Syndrome treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bronchiolitis Obliterans Syndrome Market Expected to rise, 2032 | Zambon Pharma, GlaxoSmithKline, Incyte Corporation, Mereo Biopharma, Genentech, expected to drive market

“Chronic Inflammatory Demyelinating Polyneuropathy market growth”

The Chronic Inflammatory Demyelinating Polyneuropathy market report also offers comprehensive insights into the Chronic Inflammatory Demyelinating Polyneuropathy market size, share, Chronic Inflammatory Demyelinating Polyneuropathy epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Chronic Inflammatory Demyelinating Polyneuropathy market size growth forward.

Some of the key highlights from the Chronic Inflammatory Demyelinating Polyneuropathy Market Insights Report:

• Several key pharmaceutical companies, including CSL Behring, Grifols, Kedrion Biopharma, Nihon Pharmaceutical, LFB, Teijin Pharma, OctaPharma, Shire, Takeda, UCB Biopharma, MedDay Pharmaceuticals, GeNeuro Pharmaceuticals, Pfizer, argenx, Momenta Pharmaceuticals, and others, are developing novel products to improve the Chronic Inflammatory Demyelinating Polyneuropathy treatment outlook.

• DelveInsight estimates that, in 2023, there were approximately 45,587 diagnosed cases of chronic inflammatory demyelinating polyneuropathy (CIDP) across the 7MM. Of these, the United States represented 66.3% of the cases, the EU4 and the UK accounted for nearly 29.2%, and Japan had 4.5%.

• The CIDP market is expected to experience steady growth, with a strong compound annual growth rate (CAGR) anticipated from 2024 to 2034. This growth will be driven by the introduction of innovative therapies such as riliprubart, nipocalimab, and batoclimab.

• According to DelveInsight’s analysis, the CIDP market in the 7MM was valued at approximately USD 1,780 million in 2023, and it is projected to expand at a CAGR of 7.2% from 2024 to 2034.

• Key players in the CIDP market include Octapharma, Pfizer, CSL Behring, and Takeda, which offer approved treatments like HYQVIA in the US and EU, and PRIVIGEN in the US, EU, and Japan.

• For some patients, treatments may fail to prevent disease progression or reduce frequent relapses, leading to potential disability. Moreover, there is a lack of approved therapies specifically designed for managing CIDP in patients who are prone to relapses. The off-label use of immunoglobulins limits the uptake of approved treatments like HIZENTRA and PRIVIGEN. Additionally, long-term use of corticosteroids or immunosuppressants raises the risk of infections, diabetes, and osteoporosis. In some cases, ineffective treatments fail to prevent relapses or slow disease progression, complicating the management of CIDP and resulting in disability.

• As per DelveInsight analysis, the Chronic Inflammatory Demyelinating Polyneuropathy market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Chronic Inflammatory Demyelinating Polyneuropathy Market Landscape

Chronic Inflammatory Demyelinating Polyneuropathy Overview

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological condition marked by inflammation and damage to the myelin sheath, which is the protective covering of the nerves. This damage interferes with the transmission of signals between nerves and muscles, causing progressive weakness and sensory dysfunction.

CIDP can be categorized into typical and atypical forms. The typical form, which is the most common, involves symmetrical polyneuropathy, where both proximal and distal muscles are affected equally, leading to widespread weakness and sensory issues. Symptoms typically develop slowly, though their severity varies from patient to patient, affecting mobility, fine motor abilities, and daily tasks.

Atypical CIDP includes variants such as Multifocal Acquired Demyelinating Sensory and Motor Neuropathy (MADSAM) or asymmetric CIDP, where nerve damage occurs in specific areas rather than symmetrically. Another form, Distal Acquired Demyelinating Symmetric Neuropathy (DADS), primarily affects the lower limbs and progresses at a slower rate. CIDP can also target only motor or sensory nerves.

The outcome of CIDP is heavily influenced by early diagnosis and appropriate treatment. Many patients experience significant improvements or even remission with immunomodulatory therapies. However, some cases may not respond to treatment, leading to persistent disability, and a small number of patients may have a severe, progressive form of the disease despite ongoing therapy.

Do you know the treatment paradigms for different countries? Download our Chronic Inflammatory Demyelinating Polyneuropathy Market Sample Report

Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Insights

• DelveInsight estimates that, in 2023, there were approximately 45,587 diagnosed cases of chronic inflammatory demyelinating polyneuropathy (CIDP) across the 7MM. Of these, the United States represented 66.3% of the cases, the EU4 and the UK accounted for nearly 29.2%, and Japan had 4.5%.

• The CIDP market is expected to experience steady growth, with a strong compound annual growth rate (CAGR) anticipated from 2024 to 2034. This growth will be driven by the introduction of innovative therapies such as riliprubart, nipocalimab, and batoclimab.

• According to DelveInsight’s analysis, the CIDP market in the 7MM was valued at approximately USD 1,780 million in 2023, and it is projected to expand at a CAGR of 7.2% from 2024 to 2034.

• Key players in the CIDP market include Octapharma, Pfizer, CSL Behring, and Takeda, which offer approved treatments like HYQVIA in the US and EU, and PRIVIGEN in the US, EU, and Japan.

Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Segmentation

DelveInsight’s Chronic Inflammatory Demyelinating Polyneuropathy market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Chronic Inflammatory Demyelinating Polyneuropathy historical patient pools and forecasted Chronic Inflammatory Demyelinating Polyneuropathy patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Chronic Inflammatory Demyelinating Polyneuropathy Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

• Chronic Inflammatory Demyelinating Polyneuropathy Prevalence

• Age-Specific Chronic Inflammatory Demyelinating Polyneuropathy Prevalence

• Gender-Specific Chronic Inflammatory Demyelinating Polyneuropathy Prevalence

• Diagnosed and Treatable Cases of Chronic Inflammatory Demyelinating Polyneuropathy

Visit for more @ Chronic Inflammatory Demyelinating Polyneuropathy Epidemiological Insights

Chronic Inflammatory Demyelinating Polyneuropathy Market Outlook

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare disease that has gained more attention due to improved diagnostics, greater awareness, and a better understanding of the condition. Treatment usually combines medications and supportive care, aiming to reduce inflammation, modulate the immune system, and enhance motor and sensory functions.

Corticosteroids like prednisone and dexamethasone are commonly used as initial treatments, but they come with significant long-term side effects such as osteoporosis, weight gain, and increased infection risk. These risks often require the addition of steroid-sparing agents, which may not work for all patients.

Plasma exchange has short-term benefits in removing harmful antibodies but is invasive and requires specialized centers. Intravenous immunoglobulin (IVIg) has become the preferred treatment for long-term disease management, though it is costly, time-consuming, and depends on donor plasma, raising concerns about availability.

Approved drugs for CIDP treatment focus on immune modulation, including PANZYGA, an immunoglobulin co-developed by Pfizer and Octapharma, and PRIVIGEN, an immunoglobulin offered by CSL Behring. PRIVIGEN is a room-temperature-stored, ready-to-use IVIg.

Chronic Inflammatory Demyelinating Polyneuropathy Emerging Drugs

• Riliprubart (SAR445088): Sanofi

• Nipocalimab: Janssen Research and Development

• Batoclimab (HL161): Immunovant Sciences GmbH/HanAll Pharma/Roivant Sciences

Chronic Inflammatory Demyelinating Polyneuropathy Emerging Drugs

• HYQVIA (Immune Globulin Infusion 10% [Human] with Recombinant Human Hyaluronidase): Takeda

• VYVGART HYTRULO (Efgartigimod Alfa and Hyaluronidase-Qvfc): Argenx

• GAMMAGARD LIQUID/KIOVIG (Immune Globulin Infusion [Human] 10% Solution): Takeda

Chronic Inflammatory Demyelinating Polyneuropathy Key Companies

• CSL Behring, Grifols, Kedrion Biopharma, Nihon Pharmaceutical, LFB, Teijin Pharma, OctaPharma, Shire, Takeda, UCB Biopharma, MedDay Pharmaceuticals, GeNeuro Pharmaceuticals, Pfizer, argenx, Momenta Pharmaceuticals, and others

For more information, visit Chronic Inflammatory Demyelinating Polyneuropathy Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Chronic Inflammatory Demyelinating Polyneuropathy Market Report:

• 11 Years Forecast

• 7MM Coverage

• Descriptive overview of Chronic Inflammatory Demyelinating Polyneuropathy, causes, signs and symptoms, diagnosis, treatment

• Comprehensive insight into Chronic Inflammatory Demyelinating Polyneuropathy epidemiology in the 7MM

• Chronic Inflammatory Demyelinating Polyneuropathy marketed and emerging therapies

• Chronic Inflammatory Demyelinating Polyneuropathy companies

• Chronic Inflammatory Demyelinating Polyneuropathy market drivers and barriers

Table of Contents:

1 Chronic Inflammatory Demyelinating Polyneuropathy Market Key Comprehensive Insights

2 Chronic Inflammatory Demyelinating Polyneuropathy Market Report Introduction

3 Competitive Intelligence Analysis for Chronic Inflammatory Demyelinating Polyneuropathy

4 Chronic Inflammatory Demyelinating Polyneuropathy Market Analysis Overview at a Glance

5 Executive Summary of Chronic Inflammatory Demyelinating Polyneuropathy

6 Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology and Market Methodology

7 Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology and Patient Population

8 Chronic Inflammatory Demyelinating Polyneuropathy Patient Journey

9 Chronic Inflammatory Demyelinating Polyneuropathy Treatment Algorithm, Chronic Inflammatory Demyelinating Polyneuropathy Current Treatment, and Medical Practices

10 Key Endpoints in Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials

11 Chronic Inflammatory Demyelinating Polyneuropathy Marketed Therapies

12 Chronic Inflammatory Demyelinating Polyneuropathy Emerging Therapies

13 Chronic Inflammatory Demyelinating Polyneuropathy: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Chronic Inflammatory Demyelinating Polyneuropathy

16 Chronic Inflammatory Demyelinating Polyneuropathy Market Key Opinion Leaders Reviews

18 Chronic Inflammatory Demyelinating Polyneuropathy Market Drivers

19 Chronic Inflammatory Demyelinating Polyneuropathy Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology 2034

DelveInsight’s “Chronic Inflammatory Demyelinating Polyneuropathy – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Chronic Inflammatory Demyelinating Polyneuropathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Chronic Inflammatory Demyelinating Polyneuropathy Pipeline 2024

“Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Inflammatory Demyelinating Polyneuropathy market. A detailed picture of the Chronic Inflammatory Demyelinating Polyneuropathy pipeline landscape is provided, which includes the disease overview and Chronic Inflammatory Demyelinating Polyneuropathy treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Inflammatory Demyelinating Polyneuropathy Market Expected to rise, 2034 | ICSL Behring, Grifols, Kedrion Biopharma, Nihon Pharmaceutical, LFB, Teijin Pharma, OctaPharma, Shire, Takeda, UCB Bio

“Chronic Obstructive Pulmonary Disease market growth”

The Chronic Obstructive Pulmonary Disease market report also offers comprehensive insights into the Chronic Obstructive Pulmonary Disease market size, share, Chronic Obstructive Pulmonary Disease epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Chronic Obstructive Pulmonary Disease market size growth forward.

Some of the key highlights from the Chronic Obstructive Pulmonary Disease Market Insights Report:

• Several key pharmaceutical companies, including AstraZeneca/Circassia Pharmaceuticals Inc., GlaxoSmithKline/Theravance, Inc/Innoviva, Chiesi Farmaceutici, Sunovion Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Sanofi/Regeneron Pharmaceuticals, United Therapeutics, Verona Pharma PLC, Inmunotek, Tetherex Pharmaceuticals Corporation, Novartis, Organicell Regenerative Medicine, Vertex Pharmaceuticals Incorporated, Pulmotect Inc., Genentech, Mereo BioPharma, Biomarck Pharmaceuticals, and others, are developing novel products to improve the Chronic Obstructive Pulmonary Disease treatment outlook.

• The Chronic Obstructive Pulmonary Disease (COPD) market was valued at USD 16,075 million in 2023 and is expected to see steady growth throughout the forecast period (2024–2034). This expansion is largely driven by an increase in diagnosed cases and the introduction of new therapies.

• According to DelveInsight’s analysis, approximately 41% of the total diagnosed prevalent COPD cases in the 7MM were in the United States. In 2023, estimates indicate that the EU4 and the UK collectively accounted for around 18.6 million diagnosed cases.

• The COPD market in the 7MM is primarily segmented into three treatment categories: Monotherapies (including LABA, LAMA, and others), Double Combination Therapies (such as LABA + ICS, LABA + LAMA, and other combinations), and Triple Combination Therapies (LABA + LAMA + ICS). Among these, Double Combination Therapies generated the highest revenue, amounting to approximately USD 8,803 million in 2023.

• The overall market for COPD treatments is expected to grow further during the forecast period, driven by the introduction of novel and more effective therapies such as Itepekimab (SAR440340/REGN3500), FASENRA (benralizumab), and NUCALA (mepolizumab), among others.

• In October 2024, FDA approves first monoclonal antibody for COPD

• In September 2024, Sanofi and Regeneron’s Dupixent Snags First Biologic Approval in COPD.

• In May 2024, AstraZeneca presented its latest research on major respiratory and immune-mediated diseases at ATS 2024, highlighting the strength of its pipeline and portfolio, including studies on benralizumab for COPD treatment.

• As per DelveInsight analysis, the Chronic Obstructive Pulmonary Disease market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Chronic Obstructive Pulmonary Disease Market Landscape

Chronic Obstructive Pulmonary Disease Overview

Chronic Obstructive Pulmonary Disease (COPD) is a prevalent, preventable, and treatable condition marked by persistent respiratory symptoms and airflow limitation. This occurs due to structural abnormalities in the airways and/or alveoli, typically resulting from prolonged exposure to harmful particles or gases. The development of COPD involves complex pathological mechanisms, leading to distinct subgroups with unique characteristics and progression patterns. These variations contribute to differences in exacerbation rates, airflow restriction, and lung function impairment. Managing this diversity effectively remains a major challenge in COPD treatment.

Do you know the treatment paradigms for different countries? Download our Chronic Obstructive Pulmonary Disease Market Sample Report

Chronic Obstructive Pulmonary Disease Epidemiology Insights

• According to DelveInsight’s analysis, approximately 44.2 million diagnosed prevalent cases of COPD were reported in the 7MM in 2023.

• Among these countries, the United States had the highest diagnosed prevalence of COPD. DelveInsight estimates that there were around 18.3 million diagnosed cases in the U.S. in 2023, with this number expected to rise during the forecast period. This increase is attributed to factors such as the growing prevalence of smoking, advancements in diagnostic methods, and greater awareness among patients.

Chronic Obstructive Pulmonary Disease Epidemiology Segmentation

DelveInsight’s Chronic Obstructive Pulmonary Disease market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Chronic Obstructive Pulmonary Disease historical patient pools and forecasted Chronic Obstructive Pulmonary Disease patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Chronic Obstructive Pulmonary Disease Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

• Chronic Obstructive Pulmonary Disease Prevalence

• Age-Specific Chronic Obstructive Pulmonary Disease Prevalence

• Gender-Specific Chronic Obstructive Pulmonary Disease Prevalence

• Diagnosed and Treatable Cases of Chronic Obstructive Pulmonary Disease

Visit for more @ Chronic Obstructive Pulmonary Disease Epidemiological Insights

Chronic Obstructive Pulmonary Disease Market Outlook

Chronic Obstructive Pulmonary Disease (COPD) is a widespread, preventable, and treatable lung condition affecting both men and women globally. It is characterized by airflow limitation due to airway narrowing, inflammation, mucus buildup, and lung tissue destruction. COPD shares symptoms with asthma, such as coughing, wheezing, and breathing difficulties, and some individuals may have both conditions.

While mild cases may require minimal treatment beyond smoking cessation, more advanced stages can be managed with therapies that control symptoms, slow disease progression, and reduce complications. Treatment aims to improve breathing and overall quality of life through a combination of medications, lifestyle modifications, and alternative approaches. COPD management is stage-specific, focusing on symptom relief and infection prevention.

Preventive measures, particularly smoking cessation, are crucial in slowing disease progression. Regular physical activity can also strengthen respiratory muscles and enhance well-being. Pharmacological treatment includes maintenance medications (such as inhaled corticosteroids, long-acting beta-agonists, and combination therapies) and reliever medications (such as short-acting beta-agonists, oral corticosteroids, and nebulized treatments).

Chronic Obstructive Pulmonary Disease Emerging Drugs

• Duaklir Pressair (aclidinium/formoterol fumarate): AstraZeneca

• DUPIXENT (Dupilumab): Regeneron Pharmaceuticals/Sanofi

Chronic Obstructive Pulmonary Disease Emerging Drugs

• Itepekimab (SAR440340/REGN3500): Sanofi/Regeneron Pharmaceuticals

• FASENRA (benralizumab): AstraZeneca

Chronic Obstructive Pulmonary Disease Key Companies

• AstraZeneca/Circassia Pharmaceuticals Inc., GlaxoSmithKline/Theravance, Inc/Innoviva, Chiesi Farmaceutici, Sunovion Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Sanofi/Regeneron Pharmaceuticals, United Therapeutics, Verona Pharma PLC, Inmunotek, Tetherex Pharmaceuticals Corporation, Novartis, Organicell Regenerative Medicine, Vertex Pharmaceuticals Incorporated, Pulmotect Inc., Genentech, Mereo BioPharma, Biomarck Pharmaceuticals, and others

For more information, visit Chronic Obstructive Pulmonary Disease Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Chronic Obstructive Pulmonary Disease Market Report:

• 11 Years Forecast

• 7MM Coverage

• Descriptive overview of Chronic Obstructive Pulmonary Disease, causes, signs and symptoms, diagnosis, treatment

• Comprehensive insight into Chronic Obstructive Pulmonary Disease epidemiology in the 7MM

• Chronic Obstructive Pulmonary Disease marketed and emerging therapies

• Chronic Obstructive Pulmonary Disease companies

• Chronic Obstructive Pulmonary Disease market drivers and barriers

Table of Contents:

1 Chronic Obstructive Pulmonary Disease Market Key Comprehensive Insights

2 Chronic Obstructive Pulmonary Disease Market Report Introduction

3 Competitive Intelligence Analysis for Chronic Obstructive Pulmonary Disease

4 Chronic Obstructive Pulmonary Disease Market Analysis Overview at a Glance

5 Executive Summary of Chronic Obstructive Pulmonary Disease

6 Chronic Obstructive Pulmonary Disease Epidemiology and Market Methodology

7 Chronic Obstructive Pulmonary Disease Epidemiology and Patient Population

8 Chronic Obstructive Pulmonary Disease Patient Journey

9 Chronic Obstructive Pulmonary Disease Treatment Algorithm, Chronic Obstructive Pulmonary Disease Current Treatment, and Medical Practices

10 Key Endpoints in Chronic Obstructive Pulmonary Disease Clinical Trials

11 Chronic Obstructive Pulmonary Disease Marketed Therapies

12 Chronic Obstructive Pulmonary Disease Emerging Therapies

13 Chronic Obstructive Pulmonary Disease: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Chronic Obstructive Pulmonary Disease

16 Chronic Obstructive Pulmonary Disease Market Key Opinion Leaders Reviews

18 Chronic Obstructive Pulmonary Disease Market Drivers

19 Chronic Obstructive Pulmonary Disease Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Chronic Obstructive Pulmonary Disease Epidemiology 2034

DelveInsight’s “Chronic Obstructive Pulmonary Disease – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Chronic Obstructive Pulmonary Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Chronic Obstructive Pulmonary Disease Pipeline 2024

“Chronic Obstructive Pulmonary Disease Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Obstructive Pulmonary Disease market. A detailed picture of the Chronic Obstructive Pulmonary Disease pipeline landscape is provided, which includes the disease overview and Chronic Obstructive Pulmonary Disease treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Obstructive Pulmonary Disease Market Expected to rise, 2034 | AstraZeneca/Circassia Pharmaceuticals Inc., GlaxoSmithKline/Theravance, Inc/Innoviva, Chiesi Farmaceutici, Sunovion Pharmaceutical

“Bipolar Depression Market 2034”

The Bipolar Depression market report also offers comprehensive insights into the Bipolar Depression market size, share, Bipolar Depression epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Bipolar Depression market size growth forward.

Some of the key highlights from the Bipolar Depression Market Insights Report:

• Several key pharmaceutical companies, including Allergan (AbbVie)/Gedeon Richter, Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma), Intra-Cellular Therapies, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), Lundbeck/Otsuka Pharmaceutical, Celon Pharma, COMPASS Pathways, and others, are developing novel products to improve the Bipolar Depression treatment outlook.

• In January 2025, Johnson & Johnson and Intra-Cellular Therapies announced a definitive agreement in which Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies, a biopharmaceutical company focused on developing and commercializing treatments for CNS disorders, for $132.00 per share in cash, amounting to an equity value of approximately $14.6 billion.

• In December 2024, NRx Pharmaceuticals submitted the first section of its New Drug Application (NDA) for NRX-100 (ketamine) to the FDA. NRX-100, which received Fast Track Designation in 2017, is being developed in combination with NRX-101 (D-cycloserine/lurasidone) for the treatment of suicidal bipolar depression.

• According to DelveInsight’s estimates, the total prevalent cases of Bipolar Depression in the 7MM were approximately 3.6 million in 2023, with severe cases comprising the majority (~75%) of the total cases.

• DelveInsight’s consultants estimate that Bipolar II Disorder accounted for the highest proportion of cases, making up nearly 60% of type-specific diagnosed prevalent cases of bipolar depression in the 7MM in 2023.

• Several medications have received approval from the U.S. Food and Drug Administration (FDA) for the treatment of acute bipolar depression. The olanzapine‐fluoxetine combination (OFC) was the first to receive approval in 2003, followed by quetiapine in 2006. In 2013, LATUDA (lurasidone) was approved as both a monotherapy and an adjunct to lithium or valproate for bipolar I depression. Cariprazine received approval in 2019, while CAPLYTA (lumateperone) was approved in 2021.

• The United States holds the largest market share for bipolar depression, accounting for approximately 85% compared to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

• Among the currently marketed therapies, CAPLYTA (lumateperone) is projected to achieve the highest market size in the 7MM by 2034.

• In April 2024, NRx Pharmaceuticals announced encouraging results from a Phase IIb/III clinical trial comparing NRX-101 to lurasidone for the treatment of suicidal bipolar depression. The findings suggested a promising, though not yet statistically significant, 33% reduction in suicidality along with a 70% reduction in symptoms of akathisia (P=0.076).

• As per DelveInsight analysis, the Bipolar Depression market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Bipolar Depression Market Landscape

Bipolar Depression Overview

Bipolar disorder is a condition characterized by abnormal fluctuations in mood, energy, activity levels, concentration, and the ability to perform daily tasks. It encompasses various types, including Bipolar I, Bipolar II, Cyclothymia, mixed features, and rapid cycling. Within the broader category of Bipolar Disorder, bipolar depression presents a significant clinical challenge. Despite treatment, depression remains the predominant symptom, contributing to increased morbidity and mortality due to coexisting medical conditions and a heightened risk of suicide.

Currently, there is no definitive diagnostic test for Bipolar Disorder. Diagnosis typically involves a combination of physical examination, psychiatric evaluation, mood tracking, and assessment based on established diagnostic criteria. The bipolar depression report provides an in-depth overview of the condition’s pathophysiology, diagnostic methods, and a comprehensive treatment algorithm. It also offers insights into real-world patient experiences, covering the journey from initial symptom onset to diagnosis and the full course of treatment.

Do you know the treatment paradigms for different countries? Download our Bipolar Depression Market Sample Report

Bipolar Depression Epidemiology Insights

• According to DelveInsight’s estimates, the United States accounted for approximately 70% of the total diagnosed prevalent cases of bipolar depression in the 7MM in 2023.

• Within the U.S., severe cases made up the majority, representing around 75% of the total cases based on severity.

Bipolar Depression Epidemiology Segmentation

DelveInsight’s Bipolar Depression market report is prepared on the basis of an epidemiology model. It offers comprehensive insights to the Bipolar Depression historical patient pools and forecasted Bipolar Depression patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Bipolar Depression Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

• Bipolar Depression Prevalence

• Age-Specific Bipolar Depression Prevalence

• Gender-Specific Bipolar Depression Prevalence

• Diagnosed and Treatable Cases of Bipolar Depression

Visit for more @ Bipolar Depression Epidemiological Insights

Bipolar Depression Market Outlook

Leading companies in the Bipolar Disorder market, including NeuroRx and COMPASS Pathways, are actively evaluating their key drug candidates at various stages of clinical development, aiming to explore their potential in treating bipolar depression.

Among the 7MM, the United States held the largest market share for Bipolar Disorder in 2023, valued at approximately USD 2,300 million, followed by Germany and Italy.

By 2034, NRX-100 and NRX-101 are expected to secure a significant market share for Bipolar Disorder across the 7 major markets.

Within the EU4 and the UK, Germany accounted for the highest market share (~30%) in 2023.

By 2034, CAPLYTA (lumateperone) is anticipated to dominate the Bipolar Disorder market among currently available therapies in the 7MM.

Bipolar Disorder Marketed Drugs

• VRAYLAR (Cariprazine): Allergan (AbbVie)/Gedeon Richter

• LYBALVI (olanzapine, samidorphan L-malate): Alkermes

Bipolar Depression Emerging Drugs

• COMP 360 (Psilocybin): COMPASS Pathways

• NRX-100 and NRX-101: NeuroRx

Bipolar Depression Key Companies

• Allergan (AbbVie)/Gedeon Richter, Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma), Intra-Cellular Therapies, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), Lundbeck/Otsuka Pharmaceutical, Celon Pharma, COMPASS Pathways, and others

For more information, visit Bipolar Depression Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Bipolar Depression Market Report:

• 11 Years Forecast

• 7MM Coverage

• Descriptive overview of Bipolar Depression, causes, signs and symptoms, diagnosis, treatment

• Comprehensive insight into Bipolar Depression epidemiology in the 7MM

• Bipolar Depression marketed and emerging therapies

• Bipolar Depression companies

• Bipolar Depression market drivers and barriers

Table of Contents:

1 Bipolar Depression Market Key Comprehensive Insights

2 Bipolar Depression Market Report Introduction

3 Competitive Intelligence Analysis for Bipolar Depression

4 Bipolar Depression Market Analysis Overview at a Glance

5 Executive Summary of Bipolar Depression

6 Bipolar Depression Epidemiology and Market Methodology

7 Bipolar Depression Epidemiology and Patient Population

8 Bipolar Depression Patient Journey

9 Bipolar Depression Treatment Algorithm, Bipolar Depression Current Treatment, and Medical Practices

10 Key Endpoints in Bipolar Depression Clinical Trials

11 Bipolar Depression Marketed Therapies

12 Bipolar Depression Emerging Therapies

13 Bipolar Depression: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Bipolar Depression

16 Bipolar Depression Market Key Opinion Leaders Reviews

18 Bipolar Depression Market Drivers

19 Bipolar Depression Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Bipolar Depression Epidemiology 2034

DelveInsight’s “Bipolar Depression – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Bipolar Depression epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Bipolar Depression Pipeline 2024

“Bipolar Depression Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Bipolar Depression market. A detailed picture of the Bipolar Depression pipeline landscape is provided, which includes the disease overview and Bipolar Depression treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bipolar Depression Market Expected to rise, 2034 | Allergan (AbbVie)/Gedeon Richter, Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma), Intra-Cellular Therapies, NeuroRx, Sunovion (Sumitomo Dainipp